Nava Benefits Appoints Amy Frampton CMO to Support Company's Rapid Growth
"At Nava we're committed to radically improving the benefits experience for HR teams and their employees," stated
"I'm thrilled to support Nava in its mission to fix healthcare in this country," said Frampton. "Nava is serving a critical need, making benefits easier for companies and their employees. While Nava has already made a lot of progress, I look forward to working with Brandon and the team to make even greater inroads towards the company's mission."
Frampton's hiring comes on the heels of Nava's biggest revenue year to date, during which it nearly tripled its client base. Over the past year, the company has also continued to strengthen its bench of benefits strategy experts, onboarding senior producers and service leaders from Gallagher, Mercer, Burnham, MMA, and other leading brokerage firms. In June,
About Nava Benefits
Nava is one of the fastest growing benefits brokerages in America and the first to fuse innovative technology with deep benefits expertise to make great benefits easy for growing businesses. Through delivering a better renewal strategy, benefits back-office support, and modern member support, employers turn to Nava to lower costs, delight employees, and augment HR teams. Driven by a mission to fix healthcare, Nava is proud to be recognized as part of Inc's Power Partner 2023 list as well as the 2024 New York Digital Health 100 (DH100). For more information, visit www.navabenefits.com.
Press contact: press@navabenefits.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nava-benefits-appoints-amy-frampton-cmo-to-support-companys-rapid-growth-302069421.html
SOURCE Nava Benefits
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Huawei Unveils Next-Gen Flagship Products at "Chase the Wild" Global Innovative Product Launch Event in Munich
- Asia's premier flower hub sets new benchmarks in trading scale and logistics efficiency
- Sensorion Announces Approval of Clinical Trial Application in France for SENS-601, Its Investigational Gene Therapy for the Treatment of GJB2-Related Hearing Loss
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share